Bortezomib in MCL—new standard of care or just another option?
Bortezomib in MCL—new standard of care or just another option?
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
In a recent international phase III trial, addition of bortezomib to a R-CHOP-like immunochemotherapy regimen for the first-line treatment of mantle-cell lymphoma resulted in a clinically meaningful extension of median progression-free survival. This finding emphasizes the role of targeted therapies in a relatively chemotherapy-refractory disease;...
Alternative Titles
Full title
Bortezomib in MCL—new standard of care or just another option?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A421213256
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A421213256
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/nrclinonc.2015.101
